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Abstract: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to1
examine the distribution of an intravenous contrast agent within the brain. Computational methods2
have been devised to analyse the contrast uptake/washout over time as reflections of cerebrovascular3
dysfunction. However, there have been few direct comparisons of their relative strengths and4
weaknesses. In this paper, we compare five semiquantitative methods comprising the slope and area5
under the enhancement-time curve, the slope and area under the concentration-time curve (SlopeCon6
and AUCCon), and changes in the power spectrum over time. We studied them in cerebrospinal fluid,7
normal tissues, stroke lesions, and white matter hyperintensities (WMH) using DCE-MRI scans from8
a cohort of patients with small vessel disease (SVD) who presented mild stroke. The total SVD score9
was associated with AUCCon in WMH (p < 0.05), but not with the other four methods. In WMH, we10
found higher AUCCon was associated with younger age (p < 0.001) and fewer WMH (p < 0.001),11
whereas SlopeCon increased with younger age (p > 0.05) and WMH burden (p > 0.05). Our results12
show the potential of different measures extracted from concentration-time curves extracted from the13
same DCE examination to demonstrate cerebrovascular dysfunction better than those extracted from14
enhancement-time curves.15
Keywords: Cerebrovascular alteration descriptors, small vessel disease, dynamic contrast-enhanced16
magnetic resonance imaging17
1. Introduction18
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the brain is typically19
considered for examining the integrity of grey and white matter and potential contrast leakage into20
cerebrospinal fluid (CSF) cavities [1–3]. In this imaging modality, a series of MRI scans are taken21
before and after intravenous Gadolinium-based contrast agent administration to image signal-time22
trajectories of both healthy and pathological brain regions, as illustrated in Fig. 1. Such trajectories may23
vary depending on the capillary density and the disruption of the blood-brain barrier or blood-CSF24
barrier, among other factors. Therefore, their precise analysis may help to understand better the25
mechanisms behind pathological cerebrovascular processes.26
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(a) Before contrast (b) 1 min after (c) 24 min after
Figure 1. Dynamic contrast-enhanced magnetic resonance imaging acquisition. From left to right, axial
slices of T1-w scans before, 1 min after, and 24 min after intravenous Gadolinium-based contrast agent
injection, respectively.
Computational approximations for studying signal-time trajectories are classified into two groups:27
semiquantitative and quantitative [3]. The former group of methods does not make any assumptions28
about the distribution of contrast agent within the brain, i.e. are model free. Methods that fall under29
this category analyse the area under the enhancement curve [4], signal enhancement slope [5,6],30
and dynamic spectral and texture features [7,8]. The latter group of methods describes signal-time31
curves as a result of interactions between cerebral capillaries and the extracellular extravascular space32
through pharmacokinetic modelling. The approximation consists of estimating unknown model33
parameter values from the input data through regression. However, factors such as scanner signal34
drift, tissue variations, and imaging artefacts introduce systematic errors hampering quantitative35
assessments [3,9–11].36
In this work, we study to what extent semiquantitative methods analysing signal-time trajectories37
from the same imaging acquisitions reflect cerebrovascular dysfunction. In particular, we examine the38
strength of their association with clinical parameters: the higher the percentage of variance explained39
by clinical variables, the more the relevant information the measurement captures. The considered40
methods are 1) the area under the enhancement-time curve, 2) the slope of the enhancement-time41
curve, 3) the area under the concentration-time curve, 4) the slope of the concentration-time curve,42
and 5) the radial power spectrum of the concentration-time curve. We use data from a relatively large43
cohort (n = 201) of patients who had a mild stroke and present a varied range of small vessel disease44
(SVD) features. The main finding of our work is that the analysis of concentration-time curves reflect45
key aspects of cerebrovascular dysfunction better than enhancement-time curves.46
2. Materials and methods47
The processing pipeline consists of four steps, as illustrated in Fig. 2. First, we acquire structural48
and dynamic scans for each patient in the cohort. Second, we segment all regions of interest. Third, we49
analyse contrast-time trajectories in each region. Fourth, we use ANOVA and multiple linear regression50
to establish whether measurements of contrast uptake/washout vary with any of the clinical variables.51
Further details of each step are provided in the following sections.52
2.1. Subjects, imaging, and clinical variables53
We used DCE-MRI and clinical data from 201 mild stroke patients with various extents of54
neuroimaging features of SVD [12,13]. DCE-MRI scans were obtained approximately a month after55
stroke presentation using a 3D T1-w spoiled gradient echo sequence (TR/TE = 8.24/3.1 ms, 12◦ flip56
angle, 24x24cm FoV, 0.9375x1.25x4 mm acquired resolution). Following a pre-contrast scan, patients57
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Figure 2. High level schematic of our processing pipeline. First, we acquire dynamic contrast-enhanced
scans for each patient. Second, we segment regions of interest into cerebrospinal fluid, grey matter,
normal-appearing white matter, white matter hyperintensities, and stroke lesions. Third, we analyse
contrast-time trajectories using different approaches: slopes and areas under the enhancement-time and
concentration-time curves and changes over time in the radial power spectrum. Fourth, we use ANOVA
and multiple linear regression to examine the effect of the burden of white matter hyperintensities
(Fazekas score) and all neuroimaging features of small vessel disease (Total SVD score). In Step 4, data
points located outside of the whiskers of each boxplot correspond to outliers. CSF: cerebrospinal fluid.
WMH: white matter hyperintensity. NAWM: normal-appearing white matter. GM: grey matter. SL:
stroke lesion.
were scanned after an intravenous bolus injection of 0.1mmol/kg of gadoterate meglumine (Gd-DOTA,58
Dotarem, Guerbet, France) every 73 s during 25 min (leading to 21 frames). We considered age,59
biological sex (60% male, 40% female), smoker (ever smoker 65% vs never smoker 35%), diabetes60
(yes 12% vs no 88%), hyperlipidaemia (yes 60% vs no 40%), mean arterial pressure, the total Fazekas61
score [14] (0 - 3%, 1 - 8%, 2 - 37%, 3 - 11%, 4 - 15%, 5 - 10%, and 6 - 16%) and the total SVD score [15] (0 -62
33%, 1 - 24%, 2 - 23%, 3 - 13%, and 4 - 7%).63
2.2. Segmentation of regions of interest64
We examined five regions of interest comprising cerebrospinal fluid, deep grey matter,65
normal-appearing white matter, WMH, and stroke lesions. To obtain their segment masks, we followed66
the protocol described in [12], i.e. initial segmentation using validated methods, manual edit by67
trained analysts, and mask erosion to avoid partial volume [11]. Analysts carried out the rectification68
process blinded to any other imaging and patient information. Details regarding the validation of the69
segmentation method and inter-analyst agreement can be found in [7,11,12,16].70
2.3. Methods71
2.3.1. Methods analysing the enhancement-time trajectory72
Let S[t] ∈ R, t ∈ {0, ..., T − 1} be the measured signal over time, where S[0] represents the signal
value before intravenous contrast injection and T the number of time points. Methods analysing the
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enhancement-time trajectory examine relative signal changes before and after contrast, i.e. (S[t]−
S[0])/S[0]. We estimated the area under the enhancement-time curve,
AUCEnh =
T−1
∑
t=0
S[t]− S[0]
S[0]
, (1)
and its slope,
SlopeEnh =
(T − t∗) ·∑T−1t=t∗ t · S[t]−∑T−1t=t∗ t ·∑T−1t=t∗ S[t]
(T − t∗) ·∑T−1t=t∗ t2 − (∑T−1t=t∗ t)2
, (2)
where t∗ is the time point from where the signal trend is assumed linear. Note that the formulation of73
the slope permits avoiding the peak of bolus arrival. In our case, we set t∗ = 4 after visual inspection74
of all cases in the cohort.75
2.3.2. Methods analysing the concentration-time trajectory76
Signal information and imaging parameters can be used to approximate the contrast agent
concentration [in millimoles] in time in each region of interest [9]. For that, we converted signal-time
curves to concentration-time curves by finding, c[t], that minimises the following expression
min
c[t]
∥∥∥∥∥∥S[t]− S[0]S[0] − e−r2c[t]TE
1− e−P−Q[t] − cos(θFA)
(
e−P − e−2P−Q[t]
)
1− e−P − cos(θFA)
(
e−P−Q[t] − e−2P−Q[t])
∥∥∥∥∥∥
2
2
, (3)
where P = TR/T1[0], Q[t] = r1 · c[t] · TR; r1 = 4.2s−1mM−1, r2 = 6.7s−1mM−1 are the
Gadolinium-based contrast agent relaxivities; TR = 8.24 ms and TE = 3.1 ms are the repetition and
echo times; θFA = 12◦ the flip angle; and T1[t] and T2[t] the longitudinal and transversal relaxation
times at time t, estimated as described in [9]. The relaxation time is assumed to decrease with contrast
agent concentration and relaxivities, 1/Ti[t] = 1/Ti[0] + ri · c[t], i = 1, 2. After obtaining the curves,
we estimated the area under the concentration-time curve,
AUCCon =
T−1
∑
t=0
c[t], (4)
and its slope,
SlopeCon =
(T − t∗) ·∑T−1t=t∗ t · c[t]−∑T−1t=t∗ t ·∑T−1t=t∗ c[t]
(T − t∗) ·∑T−1t=t∗ t2 − (∑T−1t=t∗ t)2
. (5)
2.3.3. Methods to analyse changes in the radial power spectrum77
The analysis of the radial power spectrum (RPS) permits scrutinising alterations in the spatial
frequency domain due to the intravenous injection of the contrast agent [17]. Similar to previous works
in the field [7,8], we computed the RPS for each region of interest and each time point after the peak of
bolus arrival by calculating the magnitude spectra and averaging it over all frequencies in concentric
rings of width one, as follows
R[s; t] =
1
K
K
∑
k=1
1
2pi
∫ 2pi
0
|Fk(s cos(θ), s sin(θ), t)| dθ, (6)
where Fk denotes the 2D discrete Fourier transform of the k-th axial slice of the input volume, K = 4278
the number of slices, and s = round
(√
u2 + v2
)
and θ = tan−1 (v/u) are polar coordinates.79
To analyse these signals that include 201 patients × 129 rings × 17 time points, we opted for
reducing their cardinality to only a set of measurements per patient. We achieved this by reducing it
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in the direction of the rings and time using the multivariate functional principal component analysis
proposed by Happ & Greven [18]. Let Rp[s; t] be the RPS over time of patient p ∈ [1, 201], s ∈ [0, 128],
t ∈ [4, 20], the overall process consists of four steps. First, we centred each variable by subtracting its
mean value across patients. Second, we computed E eigenfunctions Φk[s; t] and corresponding scores
ξpk[s] by maximising ∑p ξpk[s]
2, where
ξpk[s] =
T−1
∑
t=t∗
Φk[s; t] · Rp[s; t], (7)
subject to ||Φk[s]||2 = 1. We set E = 5 as the resulting eigenfunctions explained 99% of the data80
variance. Third, all of these scores ξpk[s] were arranged in a matrix form, Ξ ∈ R201×129×E, such81
that the pth row contained (ξp1[0], ..., ξp1[128], ..., ξp5[0], ..., ξp5[128]). Fourth, we calculated principal82
component scores by means of eigenanalysis on the covariance matrix of Ξ. We considered only the83
first mode of variation since it explained around the 98% of the data variance.84
2.4. Validation against clinical parameters85
We considered one-way analysis of variance (ANOVA) to evaluate the considered measures of86
contrast uptake/washout against clinical visual assessments related to SVD severity (i.e. Fazekas87
and total SVD scores), and multiple linear regression to establish whether age, diabetes, stroke lesion88
subtype, WMH volume, and stroke lesion volume were associated with them, after adjusting for89
biological sex, mean arterial blood pressure, hyperlipidaemia, and smoking status. For ANOVA tests,90
we used the following notation: (F(k− 1, n− k) = F-value, p, η2, ω2), where k represents the number91
of groups (i.e. 7 and 5 for Fazekas and total SVD score, respectively), n the sample size, F-value the92
F test statistic, p the p-value, and η2 and ω2 are effect size estimators which indicate the proportion93
of data variance explained by predictors. For multiple linear regression, we reported β (95% CI) and94
p-value for each predictor, which indicate their weight in the model and whether the predictor is95
significant in the model, respectively. Also, we reported the adjusted R2 values which specify the96
percentage of data variance in the outcome variable explained by predictors. We carried out our97
statistical analyses using RStudio v1.1.456 with R v3.5.1.98
3. Results99
3.1. Comparison of effect sizes100
We evaluated the effect of the measures of contrast uptake/washout computed in cerebrospinal101
fluid and WMH against two relevant visual clinical ratings (Fazekas and SVD scores).102
The effect of the burden of WMH on most vascular function measures computed from the103
cerebrospinal fluid regions was significant (AUCCon: F(6, 190) = 2.54, p < 0.05, η2 = 7%, ω2 = 5%;104
SlopeEnh: F(6, 190) = 2.87, p < 0.05, η2 = 8%, ω2 = 5%; SlopeCon: F(6, 190) = 3.71, p < 0.01,105
η2 = 11%, ω2 = 8%, RPS: F(6, 190) = 2.40, p < 0.05, η2 = 7%, ω2 = 4%), except on the AUCEnh106
(AUCEnh: F(6, 190) = 0.55, p > 0.10, η2 = 2%, ω2 = −1%), as shown in Fig. 3. The higher the107
Fazekas score, the lower the AUCs and the rising the Slopes. The association was stronger (higher η2108
and ω2) for the SlopeCon than the other four measures. The total burden of neuroimaging features of109
SVD, given by the total SVD score, was associated with the AUCCon, SlopeEnh, and SlopeCon (AUCCon:110
F(4, 192) = 2.42, p = 0.05, η2 = 5%, ω2 = 3%; SlopeEnh: F(4, 192) = 2.37, p = 0.05, η2 = 5%, ω2 = 3%;111
SlopeCon: F(4, 192) = 3.43, p < 0.01, η2 = 7%, ω2 = 5%), but not with the other measurements112
(AUCEnh: F(4, 192) = 0.48, p > 0.1, η2 = 2%, ω2 = 0%; RPS: F(4, 192) = 2.17, p > 0.05, η2 = 4%,113
ω2 = 2%). The higher the total SVD score, the lower the AUCs and RPS, the rising the Slopes.114
The impact of the burden of WMH on most measures of contrast uptake/washout from WMH115
was significant (AUCEnh: F(6, 190) = 2.61, p < 0.05, η2 = 8%, ω2 = 5%; AUCCon: F(6, 190) = 4.35,116
p < 0.001, η2 = 12%, ω2 = 9%; SlopeEnh: F(6, 190) = 2.93, p < 0.01, η2 = 9%, ω2 = 6%; SlopeCon:117
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F(6, 190) = 2.73, p < 0.05, η2 = 8%, ω2 = 5%), except on the RPS (RPS: F(6, 190) = 1.48, p > 0.10,118
η2 = 5%, ω2 = 1%), as depicted in Fig. 4. The higher the Fazekas score, the lower the AUCs and the119
rising the Slopes. The association was stronger for the AUCCon than the other four measures. The120
burden SVD features was only associated with the AUCCon (F(4, 192) = 3.09, p < 0.05, η2 = 6%,121
ω2 = 4%), but not with the other measurements (AUCEnh: F(4, 192) = 1.86, p > 0.1, η2 = 4%,122
ω2 = 2%; SlopeEnh: F(4, 192) = 1.71, p > 0.10, η2 = 3%, ω2 = 1%; SlopeCon: F(4, 192) = 2.12,123
p > 0.05, η2 = 4%, ω2 = 2%; RPS: F(4, 192) = 2.01, p > 0.05, η2 = 4%, ω2 = 2%). The higher the total124
SVD score, the lower the AUCs, the rising the Slopes.125
3.2. Relationship between contrast uptake/washout measures and clinical variables126
We carried out multiple linear regression to investigate whether age, diabetes, stroke lesion127
subtype, WMH volume, and stroke lesion volume were associated with semiquantitative measures128
of contrast uptake/washout, after adjusting for biological sex, mean arterial pressure, smoker, and129
hyperlipidaemia. Corresponding regression results are condensed in Table 1 and A1.130
In the cerebrospinal fluid region, four vascular function measures showed associations with131
clinical variables (p < 0.001), RPS did not (p > 0.1). The associations were stronger (lower132
p-value, higher coefficients of determination) when considering concentration-time curves instead of133
enhancement-time curves (AUC: R2Enh = 16% vs R
2
Con = 36%; Slope: R
2
Enh = 10% vs R
2
Con = 33%). Age134
was negatively associated the AUCs and Slopes in the CSF (AUCEnh : β = −4.27× 10−02 [95% CI −135
5.89 × 10−02, −2.65 × 10−02], p < 0.001; AUCCon : β = −1.52 × 10−02 [95% CI − 1.87 ×136
10−02, −1.17 × 10−02], p < 0.001; SlopeEnh : β = −3.51 × 10−05 [95% CI − 5.27 × 10−05, −1.76 ×137
10−05], p < 0.001; SlopeCon : β = −1.29× 10−05 [95% CI − 1.61× 10−05, −9.66× 10−06], p < 0.001).138
Clinical parameters predicted most variance in AUCCon values compared to the four other methods139
(Adjusted R2 : AUCCon = 36% vs SlopeCon = 33, RPS = 2%, AUCEnh = 16%, SlopeEnh = 10%).140
In the deep grey matter, AUCCon, SlopeCon, and RPS showed associations with clinical variables.141
Age was a strong predictor was negatively associated with AUCCon and SlopeCon (AUCCon :142
β = −2.29 × 10−03 [95% CI − 3.29 × 10−03, −1.30 × 10−03], p < 0.001; SlopeCon : β = −1.35 ×143
10−06 [95% CI − 2.43× 10−06, −2.59× 10−07], p < 0.05). A diagnosis of diabetes was associated with144
an increase in the AUCCon (AUCCon : β = 5.37× 10−02 [95% CI 2.28× 10−02, 8.46× 10−02], p < 0.001).145
WMH volume was negatively associated with the RPS (RPS : β = −3.19× 1003 [95% CI − 5.51×146
1003, −8.81× 1003], p < 0.01). Clinical parameters predicted the variance in AUCCon values the best147
compared to other methods (Adjusted R2 : AUCCon = 13% vs SlopeCon = 8, RPS = 5%, AUCEnh =148
3%, SlopeEnh = 3%).149
In normal-appearing white matter, clinical parameters were weakly or not associated with the150
five measures of vascular function (i.e. 0.01 < p < 0.05 and p > 0.1, respectively) as they explained151
between 1% and 6% of their variability. Age predicted the AUCCon significantly (AUCCon : β =152
−1.81× 10−03 [95% CI − 2.70× 10−03, −9.08× 10−04], p < 0.001).153
In WMH, clinical variables predicted 13% and 25% of the variance in AUCEnh and AUCCon154
(p < 0.001). Age, diabetes, and WMH volume were significantly and consistently associated with155
AUCEnh and AUCCon (p < 0.05 and p < 0.01, respectively). An increase in AUCEnh and AUCCon156
was associated with younger age (AUCEnh : β = −6.81× 10−03 [95% CI − 1.26× 10−02, −1.07×157
10−03], p < 0.05; AUCCon : β = −2.88× 10−03 [95% CI − 4.07× 10−03, −1.69× 10−03], p < 0.001),158
diabetes diagnosis (AUCEnh : β = 2.72× 10−01 [95% CI 9.31× 10−01, 4.51× 10−01], p < 0.01; AUCCon :159
β = 6.13× 10−02 [95% CI 2.44× 10−02, 9.82× 10−02], p < 0.01), and less WMH volume (AUCEnh :160
β = −4.46 [95% CI − 7.17, −1.75], p < 0.01; AUCCon : β = −1.08 [95% CI − 1.63, −0.52], p < 0.001).161
Moreover, the stroke lesion volume was positively associated with the AUCEnh (AUCEnh : β =162
6.38 [95% CI 1.05, 11.7], p < 0.01).163
In stroke lesions, all vascular function measures were associated with clinical variables (p < 0.05).164
The associations between clinical parameters and AUCEnh and AUCCon were clearer compared to165
those of the rest (28% ≤ R2 ≤ 33% vs 4% ≤ R2 ≤ 14%). Three variables strongly predicted166
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Figure 3. Estimated contrast uptake/washout extracted from cerebrospinal fluid for patients grouped
by their (a) Fazekas and (b) total SVD scores. We computed the p-values using the ANOVA test. Data
points located outside of the whiskers of each boxplot correspond to outliers.
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Figure 4. Estimated contrast uptake/washout extracted from white matter hyperintensities for patients
grouped by their (a) Fazekas and (b) total SVD scores. We computed the p-values using the ANOVA
test. Data points located outside of the whiskers of each boxplot correspond to outliers.
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Table 1. Adjusted R2 and p-values of multiple linear regression with semiquantitative contrast
uptake/washout estimates per region of interest as predicted variables and clinical parameters as
predictors. This table is a simplified version of Table A1. Adjusted R2 values are shown as percentages.
Significant associations appear in bold. Stroke type: 0 - cortical, 1 - lacunar. ROI: region of interest. CI:
confidence interval. CSF: cerebrospinal fluid. DGM: deep grey matter. NAWM: normal-appearing
white matter. WMH: white matter hyperintensity. SL: stroke lesion. RPS: radial power spectrum.
Stroke WMH SL
ROI Method R2 p-value Age Diabetes type volume volume
CSF
AUCEnh 16 2.17e-06 5.02e-07 5.85e-01 7.88e-01 3.90e-01 1.61e-01
AUCCon 36 4.44e-16 3.77e-15 8.32e-01 7.35e-01 7.69e-01 9.61e-01
SlopeEnh 10 5.92e-04 1.12e-04 1.56e-01 6.24e-01 1.55e-01 4.43e-01
SlopeCon 33 9.97e-15 2.46e-13 2.19e-01 3.98e-01 4.76e-01 2.03e-01
RPS 2 1.78e-01 8.97e-01 7.46e-01 7.10e-01 6.79e-02 3.64e-01
DGM
AUCEnh 3 8.11e-02 2.97e-01 2.75e-02 4.51e-01 8.53e-02 1.12e-01
AUCCon 13 6.20e-05 9.30e-06 7.47e-04 6.04e-01 7.75e-01 8.18e-01
SlopeEnh 3 9.77e-02 1.93e-01 6.31e-01 6.54e-01 3.97e-01 6.90e-01
SlopeCon 8 3.59e-03 1.55e-02 3.23e-01 7.59e-01 1.20e-01 9.86e-01
RPS 5 3.33e-02 4.89e-01 1.09e-01 8.24e-01 7.05e-03 4.57e-01
NAWM
AUCEnh 3 1.27e-01 2.68e-01 6.64e-01 4.53e-01 2.47e-02 5.82e-01
AUCCon 6 1.07e-02 1.03e-04 1.83e-01 3.84e-01 6.17e-01 3.19e-01
SlopeEnh -1 5.94e-01 7.04e-01 9.14e-01 2.27e-01 2.55e-01 3.50e-01
SlopeCon 2 1.43e-01 2.73e-01 5.44e-01 1.94e-01 1.08e-01 1.09e-01
RPS -2 8.53e-01 9.57e-01 8.11e-01 5.49e-01 8.13e-01 9.97e-01
WMH
AUCEnh 13 3.60e-05 2.04e-02 3.07e-03 7.86e-01 1.37e-03 1.93e-02
AUCCon 25 2.49e-10 3.38e-06 1.25e-03 9.94e-01 1.98e-04 8.61e-01
SlopeEnh 4 6.11e-02 4.59e-01 5.35e-01 2.79e-01 4.04e-01 1.21e-01
SlopeCon 4 7.23e-02 6.88e-02 2.92e-01 3.00e-01 3.25e-01 7.95e-01
RPS -3 9.58e-01 4.82e-01 3.88e-01 4.72e-01 8.78e-01 6.12e-01
SL
AUCEnh 33 9.90e-10 5.04e-01 3.43e-05 1.52e-05 1.07e-01 8.69e-04
AUCCon 28 6.33e-08 2.21e-01 6.73e-08 1.92e-03 7.88e-02 6.87e-02
SlopeEnh 14 6.30e-04 6.69e-01 5.05e-02 6.02e-02 1.63e-01 4.36e-04
SlopeCon 13 1.02e-03 3.41e-01 1.28e-03 2.17e-02 1.04e-01 7.06e-02
RPS 4 4.51e-02 9.52e-01 6.26e-01 6.31e-01 2.95e-02 1.34e-03
the outcome variables for some of these models: diabetes, stroke lesion subtype, and stroke lesion167
volume. A diagnosis of diabetes was significantly associated with an increase in AUCs and Slopes168
(AUCEnh : β = 1.13 [95% CI 0.61, 1.65], p < 0.001; AUCCon : β = 0.31 [95% CI 0.20, 0.41], p <169
0.001; SlopeEnh : β = 6.85× 10−04 [95% CI − 1.45× 10−06, 1.37× 10−03], p = 0.05; SlopeCon : β =170
2.60 × 10−04 [95% CI 1.04 × 10−04, 4.16 × 10−04], p < 0.01), but not with RPS (p > 0.1). Cortical171
strokes had higher AUCs and SlopeCon (AUCEnh : β = −0.83 [95% CI − 1.20, −0.47], p < 0.001;172
AUCCon : β = −0.12 [95% CI − 0.19, −0.05], p < 0.01; SlopeCon : β = −1.29× 10−04 [95% CI −173
2.38× 10−04, −1.92× 10−05], p < 0.05). Stroke volume was associated with an increase in AUCEnh,174
SlopeEnh, and RPS (AUCEnh : β = 2.41× 1001 [95% CI 1.01× 1001, 3.82× 1001], p < 0.001; SlopeEnh :175
β = 3.37× 10−02 [95% CI 1.52× 10−02, 5.22× 10−02], p < 0.001; RPS : β = 7.16× 1003 [95% CI 2.82×176
1003, 1.15× 1004], p < 0.01).177
4. Discussion178
In this work, we compared the performance of five semiquantitative methods for analysing179
signal-time trajectories of Gadolinium-based contrast agent in reflecting small vessel disease burden180
within healthy and pathological intracranial brain regions. The five methods estimate and analyse the181
slopes and area under the enhancement-time and concentration-time curves and changes in the power182
spectrum of the contrast-enhancement signal over time.183
The considered semiquantitative measurements assessing contrast uptake/washout provide184
different yet complementary information related to cerebrovascular dysfunction. First, the areas185
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under the enhancement-time/concentration-time curves describe two processes that may cause signal186
change in tissue jointly: accumulation of contrast agent in the extravascular extracellular space due to187
blood-brain barrier leakage and total volume of blood. Since the former effect is expected to be subtle188
in small vessel disease, we expect these areas under the curves to reflect more total blood volume. In189
regions filled with cerebrospinal fluid, increases in areas under the curves could be caused by contrast190
agent leakage due to an impaired blood-cerebrospinal fluid barrier [1–3]. Second, the slopes of the191
enhancement-time/concentration-time curves describe the rate at which the contrast agent washes out192
of brain tissues. While a positive slope reflects uptake of contrast agent in tissue over time, a negative193
slope reflects contrast washout over time. The magnitude of such a change indicates the speed at194
which it happens: the higher the magnitude, the faster the change over time. Thus, the slower the195
washout rate, the more the contrast agent stays in tissue potentially due to its accumulation in the196
extracellular extravascular space. In regions filled with cerebrospinal fluid, a slope different from zero197
may reveal impairment of the blood-CSF barrier. Third, the analysis of the radial power spectrum198
permits quantifying changes in frequencies over time cohort-wise [8]. A positive or negative value199
expresses distancing from the mean behaviour (described by each eigenfunction) cohort-wise.200
We performed a one-way ANOVA to determine the effect of the burden of WMH and201
neuroimaging features of SVD, expressed in terms of the Fazekas and total SVD scores, on the202
five measures of contrast uptake/washout from CSF and WMH. Most effects were significant on203
measurements extracted from both CSF and WMH considering Fazekas scores. The only significant204
effects when considering the total SVD score were the slope of the concentration-time curve extracted205
from regions filled with CSF and the area under the concentration-time extracted from WMH. These206
results imply that most measurements vary depending on the overall burden of WMH in the brain,207
but only concentration-time measurements capture additional aspects of vascular dysfunction on208
univariate analyses. Moreover, the relationship between measurements and clinical visual scores was209
more evident (lower p-values) when extracted from concentration-time curves. Therefore, the analysis210
of concentration-time curves is more reliable than enhancement-time curves since the former includes211
adjustment for contrast agent relaxivities, imaging parameters, and relaxation times of each region of212
interest. The slopes and areas under the curves exhibited opposite trends: slopes increased with WMH213
and total SVD score, whilst areas decreased. Examination on larger datasets with more varied states of214
brain vascular and other pathologies is needed to more fully understand the factors influencing the215
measurement of these potentially valuable differential vascular dysfunction parameters.216
We performed multiple linear regression to establish whether clinical parameters (age, biological217
sex, mean arterial pressure, hyperlipidaemia, smoker, diabetes, stroke lesion subtype, WMH and218
stroke lesion volume) determined the extent of enhancement in cerebrospinal fluid, deep grey matter,219
normal-appearing white matter, WMH, and stroke lesion. The strength of the associations were220
consistently higher when considering measurements from the concentration-time curves and not from221
the enhancement-time curves consistent with the literature [1,4–6,19–23]. This might imply that the222
use of imaging parameters to obtain these former trajectories provide better estimates of the contrast223
uptake/washout. While the analysis of the area under the concentration-time curve was explained the224
best by clinical parameters regardless of the region of interest, the analysis of the radial power spectrum225
did not identify associations as they were the weakest compared to the other four measurements.226
The presence of noise and signal drift in similar levels to the signal changes has been acknowledged227
previously [9,24]. The RPS, reflective of the cumulative effect of the whole frequency spectrum forming228
the signal, is a sensitive measure worth further evaluation for this purpose once appropriate noise229
filtering procedures have been applied.230
Estimates of contrast agent update/washout in cerebrospinal fluid-filled spaces, deep grey matter,231
normal-appearing white matter, and WMH were negatively associated with age. Given that the total232
volume of blood decreases with age [25] and that leakage in small vessel disease is expected to be233
subtle [3], this outcome suggests that the enhancement in the capillaries might be overshadowing234
the enhancement due to leakage and, hence, the semiquantitative methods considered in this work235
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examine vascular surface area, in accordance with previous research in the field [26]. In WMH regions,236
our results indicate that their enhancement decreases with the extent of demyelination and axonal237
damage [27], consistent with previous findings [28–30]. In deep grey matter, WMH, and stroke238
lesions, diabetes influenced the contrast uptake/washout estimates: higher values in diabetic vs239
non-diabetic patients. This outcome suggests that diabetic patients may present a reduction in capillary240
density or a higher impairment of the blood-brain barrier. In both cases, this relationship agrees with241
previous studies in which both hyper- and hypo-glycemia have been associated with cerebrovascular242
alterations [31] and compromised the blood-brain barrier [32,33]. In stroke lesions, large cortical strokes243
exhibited the highest contrast uptake/washout estimates, much more evident in diabetic patients.244
Further research in these directions is needed to account for the interaction between the capillaries and245
the extracellular extravascular space and their contribution to the overall enhancement.246
Future work should consider comparing more semiquantitative and quantitative approaches for247
analysing concentration-time curves and assessing their robustness against imaging artefacts as they248
compromise current assessments [3,9–11].249
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Abbreviations268
The following abbreviations are used in this manuscript:269
270
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ANOVA Analysis of variance
AUC Area under the curve
AUCCon Area under the concentration-time curve
AUCEnh Area under the enhancement-time curve
CI Confidence interval
CSF Blood-brain barrier
DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging
DGM Deep grey matter
MAP Mean arterial pressure
MRI Magnetic resonance imaging
NAWM Normal-appearing white matter
WMH White matter hyperintensity
RPS Radial power spectrum
SL Stroke lesion
SlopeCon Slope of the concentration-time curve
SlopeEnh Slope of the enhancement-time curve
SVD Small vessel disease
TE Echo time
TI Inversion time
TR Repetition time
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Table A1. Multiple linear regression results with semiquantitative contrast uptake/washout estimates per region of interest as predicted variables and clinical
parameters as predictors. Adjusted R2 values are shown as percentages. Biological sex: 0 - female, 1 - male. Stroke type: 0 - cortical, 1 - lacunar. ROI: region of
interest. MAP: mean arterial pressure. CI: confidence interval. CSF: cerebrospinal fluid. DGM: deep grey matter. NAWM: normal-appearing white matter. WMH:
white matter hyperintensity. SL: stroke lesion. RPS: radial power spectrum.
ROI Method R2 p-value Age Biological sex MAP Hyperlipidaemia Smoker Diabetes Stroke type WMH volume SL volume
β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value
C
S
F
AUCEnh 16 2.17e-06 -4.27e-02 5.02e-07 -5.46e-01 1.40e-03 -4.41e-03 4.25e-01 -1.10e-01 5.17e-01 -9.63e-02 5.84e-01 -1.40e-01 5.85e-01 -4.65e-02 7.88e-01 3.33e+00 3.90e-01 1.07e+01 1.61e-01
(-5.89e-02, -2.65e-02) (-8.78e-01, -2.14e-01) (-1.53e-02, 6.48e-03) (-4.44e-01, 2.24e-01) (-4.42e-01, 2.50e-01) (-6.44e-01, 3.64e-01) (-3.88e-01, 2.95e-01) (-4.30e+00, 1.10e+01) (-4.32e+00, 2.57e+01)
AUCCon 36 4.44e-16 -1.52e-02 3.77e-15 -1.40e-01 1.61e-04 -9.58e-04 4.23e-01 -3.73e-02 3.09e-01 1.18e-02 7.56e-01 -1.17e-02 8.32e-01 -1.27e-02 7.35e-01 2.46e-01 7.69e-01 -8.12e-02 9.61e-01
(-1.87e-02, -1.17e-02) (-2.12e-01, -6.84e-02) (-3.31e-03, 1.39e-03) (-1.10e-01, 3.48e-02) (-6.30e-02, 8.67e-02) (-1.21e-01, 9.72e-02) (-8.65e-02, 6.12e-02) (-1.40e+00, 1.89e+00) (-3.33e+00, 3.17e+00)
SlopeEnh 10 5.92e-04 -3.51e-05 1.12e-04 -1.50e-04 4.14e-01 -6.13e-06 3.07e-01 -1.98e-05 9.14e-01 -1.32e-04 4.88e-01 3.95e-04 1.56e-01 -9.23e-05 6.24e-01 -5.99e-03 1.55e-01 6.36e-03 4.43e-01
(-5.27e-05, -1.76e-05) (-5.10e-04, 2.11e-04) (-1.79e-05, 5.68e-06) (-3.82e-04, 3.42e-04) (-5.08e-04, 2.43e-04) (-1.52e-04, 9.41e-04) (-4.63e-04, 2.78e-04) (-1.43e-02, 2.28e-03) (-9.95e-03, 2.27e-02)
SlopeCon 33 9.97e-15 -1.29e-05 2.46e-13 -1.19e-04 4.97e-04 -1.71e-06 1.20e-01 -3.71e-06 9.12e-01 1.58e-05 6.51e-01 6.27e-05 2.19e-01 -2.92e-05 3.98e-01 -5.49e-04 4.76e-01 1.94e-03 2.03e-01
(-1.61e-05, -9.66e-06) (-1.85e-04, -5.27e-05) (-3.88e-06, 4.51e-07) (-7.01e-05, 6.27e-05) (-5.31e-05, 8.47e-05) (-3.76e-05, 1.63e-04) (-9.72e-05, 3.88e-05) (-2.07e-03, 9.68e-04) (-1.05e-03, 4.93e-03)
RPS 2 1.78e-01 -5.43e-01 8.97e-01 2.94e+01 7.32e-01 -8.39e-01 7.66e-01 -2.16e+01 8.02e-01 1.85e+02 3.95e-02 -4.23e+01 7.46e-01 3.29e+01 7.10e-01 -3.62e+03 6.79e-02 -3.53e+03 3.64e-01
(-8.80e+00, 7.71e+00) (-1.40e+02, 1.99e+02) (-6.39e+00, 4.71e+00) (-1.92e+02, 1.49e+02) (8.97e+00, 3.62e+02) (-2.99e+02, 2.15e+02) (-1.41e+02, 2.07e+02) (-7.50e+03, 2.69e+02) (-1.12e+04, 4.13e+03)
D
G
M
AUCEnh 3 8.11e-02 -2.55e-03 2.97e-01 3.37e-02 5.02e-01 -8.73e-04 5.95e-01 -2.97e-02 5.56e-01 -8.02e-02 1.26e-01 1.69e-01 2.75e-02 3.89e-02 4.51e-01 1.99e+00 8.53e-02 3.62e+00 1.12e-01
(-7.37e-03, 2.26e-03) (-6.51e-02, 1.33e-01) (-4.11e-03, 2.36e-03) (-1.29e-01, 6.96e-02) (-1.83e-01, 2.28e-02) (1.89e-02, 3.19e-01) (-6.27e-02, 1.41e-01) (-2.79e-01, 4.26e+00) (-8.48e-01, 8.09e+00)
AUCCon 13 6.20e-05 -2.29e-03 9.30e-06 -5.52e-03 5.94e-01 -8.96e-05 7.92e-01 -1.53e-02 1.41e-01 -7.05e-03 5.13e-01 5.37e-02 7.47e-04 5.52e-03 6.04e-01 -6.77e-02 7.75e-01 -1.08e-01 8.18e-01
(-3.29e-03, -1.30e-03) (-2.59e-02, 1.49e-02) (-7.57e-04, 5.78e-04) (-3.58e-02, 5.13e-03) (-2.83e-02, 1.42e-02) (2.28e-02, 8.46e-02) (-1.54e-02, 2.65e-02) (-5.35e-01, 4.00e-01) (-1.03e+00, 8.14e-01)
SlopeEnh 3 9.77e-02 -3.00e-06 1.93e-01 -1.27e-04 7.73e-03 -2.50e-06 1.07e-01 3.72e-05 4.32e-01 1.83e-05 7.09e-01 3.43e-05 6.31e-01 2.17e-05 6.54e-01 -9.17e-04 3.97e-01 8.51e-04 6.90e-01
(-7.52e-06, 1.53e-06) (-2.20e-04, -3.39e-05) (-5.54e-06, 5.42e-07) (-5.60e-05, 1.30e-04) (-7.84e-05, 1.15e-04) (-1.06e-04, 1.75e-04) (-7.37e-05, 1.17e-04) (-3.05e-03, 1.21e-03) (-3.35e-03, 5.05e-03)
SlopeCon 8 3.59e-03 -1.35e-06 1.55e-02 -2.94e-05 1.01e-02 -4.97e-07 1.81e-01 7.61e-06 5.04e-01 9.31e-06 4.30e-01 1.70e-05 3.23e-01 3.57e-06 7.59e-01 -4.05e-04 1.20e-01 -8.70e-06 9.86e-01
(-2.43e-06, -2.59e-07) (-5.17e-05, -7.08e-06) (-1.23e-06, 2.33e-07) (-1.48e-05, 3.00e-05) (-1.39e-05, 3.25e-05) (-1.68e-05, 5.08e-05) (-1.94e-05, 2.65e-05) (-9.17e-04, 1.06e-04) (-1.02e-03, 1.00e-03)
RPS 5 3.33e-02 1.73e+00 4.89e-01 -6.55e+01 2.02e-01 -2.14e+00 2.03e-01 -2.09e+01 6.84e-01 5.72e+01 2.84e-01 -1.25e+02 1.09e-01 1.17e+01 8.24e-01 -3.19e+03 7.05e-03 -1.72e+03 4.57e-01
(-3.18e+00, 6.64e+00) (-1.66e+02, 3.53e+01) (-5.44e+00, 1.16e+00) (-1.22e+02, 8.04e+01) (-4.78e+01, 1.62e+02) (-2.77e+02, 2.82e+01) (-9.19e+01, 1.15e+02) (-5.51e+03, -8.81e+02) (-6.28e+03, 2.84e+03)
N
A
W
M
AUCEnh 3 1.27e-01 -1.58e-03 2.68e-01 -3.34e-02 2.54e-01 -5.93e-04 5.35e-01 -1.65e-02 5.74e-01 -6.89e-02 2.45e-02 1.92e-02 6.64e-01 -2.25e-02 4.53e-01 1.51e+00 2.47e-02 7.27e-01 5.82e-01
(-4.38e-03, 1.23e-03) (-9.09e-02, 2.42e-02) (-2.48e-03, 1.29e-03) (-7.43e-02, 4.13e-02) (-1.29e-01, -8.95e-03) (-6.80e-02, 1.06e-01) (-8.17e-02, 3.66e-02) (1.95e-01, 2.83e+00) (-1.88e+00, 3.33e+00)
AUCCon 6 1.07e-02 -1.81e-03 1.03e-04 -7.85e-03 4.02e-01 -4.70e-05 8.78e-01 -9.61e-03 3.07e-01 -1.48e-02 1.30e-01 1.89e-02 1.83e-01 -8.38e-03 3.84e-01 1.07e-01 6.17e-01 -4.22e-01 3.19e-01
(-2.70e-03, -9.08e-04) (-2.63e-02, 1.06e-02) (-6.50e-04, 5.56e-04) (-2.81e-02, 8.90e-03) (-3.40e-02, 4.38e-03) (-8.99e-03, 4.69e-02) (-2.73e-02, 1.06e-02) (-3.15e-01, 5.30e-01) (-1.25e+00, 4.12e-01)
SlopeEnh -1 5.94e-01 6.78e-07 7.04e-01 -2.42e-05 5.09e-01 -1.43e-08 9.90e-01 6.60e-05 7.40e-02 2.84e-05 4.58e-01 -5.99e-06 9.14e-01 -4.56e-05 2.27e-01 -9.58e-04 2.55e-01 -1.55e-03 3.50e-01
(-2.84e-06, 4.19e-06) (-9.64e-05, 4.80e-05) (-2.38e-06, 2.35e-06) (-6.48e-06, 1.39e-04) (-4.68e-05, 1.04e-04) (-1.15e-04, 1.03e-04) (-1.20e-04, 2.87e-05) (-2.61e-03, 6.98e-04) (-4.81e-03, 1.72e-03)
SlopeCon 2 1.43e-01 -6.60e-07 2.73e-01 -7.77e-06 5.29e-01 2.02e-07 6.16e-01 1.94e-05 1.19e-01 9.82e-06 4.45e-01 1.14e-05 5.44e-01 -1.65e-05 1.94e-01 -4.56e-04 1.08e-01 -8.97e-04 1.09e-01
(-1.84e-06, 5.23e-07) (-3.21e-05, 1.65e-05) (-5.93e-07, 9.98e-07) (-5.01e-06, 4.38e-05) (-1.55e-05, 3.51e-05) (-2.55e-05, 4.82e-05) (-4.15e-05, 8.48e-06) (-1.01e-03, 1.02e-04) (-2.00e-03, 2.01e-04)
RPS -2 8.53e-01 2.36e-01 9.57e-01 1.59e+02 7.85e-02 1.39e-01 9.62e-01 1.52e+01 8.67e-01 9.35e+01 3.19e-01 3.26e+01 8.11e-01 5.55e+01 5.49e-01 4.87e+02 8.13e-01 -1.74e+01 9.97e-01
(-8.40e+00, 8.87e+00) (-1.83e+01, 3.36e+02) (-5.67e+00, 5.94e+00) (-1.63e+02, 1.93e+02) (-9.12e+01, 2.78e+02) (-2.36e+02, 3.01e+02) (-1.27e+02, 2.38e+02) (-3.58e+03, 4.55e+03) (-8.04e+03, 8.00e+03)
W
M
H
AUCEnh 13 3.60e-05 -6.81e-03 2.04e-02 5.37e-02 3.70e-01 2.29e-04 9.07e-01 -1.68e-02 7.80e-01 -1.73e-02 7.81e-01 2.72e-01 3.07e-03 1.67e-02 7.86e-01 -4.46e+00 1.37e-03 6.38e+00 1.93e-02
(-1.26e-02, -1.07e-03) (-6.42e-02, 1.72e-01) (-3.63e-03, 4.09e-03) (-1.35e-01, 1.02e-01) (-1.40e-01, 1.06e-01) (9.31e-02, 4.51e-01) (-1.05e-01, 1.38e-01) (-7.17e+00, -1.75e+00) (1.05e+00, 1.17e+01)
AUCCon 25 2.49e-10 -2.88e-03 3.38e-06 1.96e-02 1.15e-01 1.20e-04 7.67e-01 -1.30e-02 2.95e-01 -4.53e-03 7.25e-01 6.13e-02 1.25e-03 -1.02e-04 9.94e-01 -1.08e+00 1.98e-04 -9.75e-02 8.61e-01
(-4.07e-03, -1.69e-03) (-4.78e-03, 4.39e-02) (-6.78e-04, 9.17e-04) (-3.75e-02, 1.14e-02) (-2.99e-02, 2.08e-02) (2.44e-02, 9.82e-02) (-2.51e-02, 2.49e-02) (-1.63e+00, -5.17e-01) (-1.20e+00, 1.00e+00)
SlopeEnh 4 6.11e-02 -2.23e-06 4.59e-01 -1.61e-04 9.94e-03 -1.01e-06 6.18e-01 1.11e-04 7.47e-02 8.52e-05 1.87e-01 5.82e-05 5.35e-01 -6.90e-05 2.79e-01 1.19e-03 4.04e-01 4.35e-03 1.21e-01
(-8.17e-06, 3.70e-06) (-2.83e-04, -3.90e-05) (-5.00e-06, 2.98e-06) (-1.12e-05, 2.34e-04) (-4.18e-05, 2.12e-04) (-1.27e-04, 2.43e-04) (-1.94e-04, 5.63e-05) (-1.61e-03, 3.98e-03) (-1.16e-03, 9.87e-03)
SlopeCon 4 7.23e-02 -1.32e-06 6.88e-02 -3.76e-05 1.18e-02 -2.34e-07 6.30e-01 2.53e-05 9.04e-02 2.03e-05 1.91e-01 2.37e-05 2.92e-01 -1.58e-05 3.00e-01 3.35e-04 3.25e-01 1.74e-04 7.95e-01
(-2.74e-06, 1.03e-07) (-6.68e-05, -8.43e-06) (-1.19e-06, 7.22e-07) (-4.03e-06, 5.47e-05) (-1.02e-05, 5.07e-05) (-2.06e-05, 6.80e-05) (-4.58e-05, 1.42e-05) (-3.35e-04, 1.00e-03) (-1.15e-03, 1.50e-03)
RPS -3 9.58e-01 1.90e+00 4.82e-01 5.00e+01 3.68e-01 9.04e-01 6.19e-01 -2.76e+01 6.21e-01 1.13e+01 8.45e-01 -7.28e+01 3.88e-01 -4.11e+01 4.72e-01 1.96e+02 8.78e-01 -1.27e+03 6.12e-01
(-3.43e+00, 7.23e+00) (-5.94e+01, 1.59e+02) (-2.68e+00, 4.49e+00) (-1.37e+02, 8.23e+01) (-1.03e+02, 1.25e+02) (-2.39e+02, 9.31e+01) (-1.54e+02, 7.14e+01) (-2.31e+03, 2.71e+03) (-6.22e+03, 3.67e+03)
S
L
AUCEnh 33 9.90e-10 5.95e-03 5.04e-01 2.28e-01 2.06e-01 2.36e-03 6.82e-01 2.18e-01 2.15e-01 1.40e-01 4.38e-01 1.13e+00 3.43e-05 -8.31e-01 1.52e-05 -6.66e+00 1.07e-01 2.41e+01 8.69e-04
(-1.16e-02, 2.35e-02) (-1.27e-01, 5.83e-01) (-9.03e-03, 1.38e-02) (-1.28e-01, 5.65e-01) (-2.16e-01, 4.96e-01) (6.10e-01, 1.65e+00) (-1.20e+00, -4.65e-01) (-1.48e+01, 1.45e+00) (1.01e+01, 3.82e+01)
AUCCon 28 6.33e-08 -2.22e-03 2.21e-01 5.17e-02 1.58e-01 6.43e-04 5.82e-01 3.20e-02 3.70e-01 1.98e-02 5.88e-01 3.06e-01 6.73e-08 -1.19e-01 1.92e-03 -1.47e+00 7.88e-02 2.63e+00 6.87e-02
(-5.78e-03, 1.35e-03) (-2.02e-02, 1.24e-01) (-1.67e-03, 2.95e-03) (-3.83e-02, 1.02e-01) (-5.23e-02, 9.20e-02) (2.00e-01, 4.11e-01) (-1.93e-01, -4.45e-02) (-3.11e+00, 1.72e-01) (-2.05e-01, 5.47e+00)
SlopeEnh 14 6.30e-04 5.02e-06 6.69e-01 1.69e-04 4.77e-01 2.74e-06 7.19e-01 1.45e-04 5.30e-01 2.41e-04 3.12e-01 6.85e-04 5.05e-02 -4.62e-04 6.02e-02 -7.57e-03 1.63e-01 3.37e-02 4.36e-04
(-1.81e-05, 2.82e-05) (-2.99e-04, 6.37e-04) (-1.23e-05, 1.78e-05) (-3.12e-04, 6.03e-04) (-2.28e-04, 7.10e-04) (-1.45e-06, 1.37e-03) (-9.44e-04, 2.01e-05) (-1.83e-02, 3.12e-03) (1.52e-02, 5.22e-02)
SlopeCon 13 1.02e-03 -2.54e-06 3.41e-01 5.33e-05 3.24e-01 1.43e-06 4.08e-01 3.69e-05 4.84e-01 8.71e-06 8.72e-01 2.60e-04 1.28e-03 -1.29e-04 2.17e-02 -2.01e-03 1.04e-01 3.87e-03 7.06e-02
(-7.81e-06, 2.73e-06) (-5.32e-05, 1.60e-04) (-1.98e-06, 4.85e-06) (-6.71e-05, 1.41e-04) (-9.81e-05, 1.15e-04) (1.04e-04, 4.16e-04) (-2.38e-04, -1.92e-05) (-4.44e-03, 4.20e-04) (-3.30e-04, 8.07e-03)
RPS 4 4.51e-02 1.43e-01 9.52e-01 3.15e+01 5.18e-01 5.64e-01 7.23e-01 -2.27e+01 6.42e-01 1.45e+01 7.75e-01 -3.59e+01 6.26e-01 2.40e+01 6.31e-01 2.45e+03 2.95e-02 7.16e+03 1.34e-03
(-4.53e+00, 4.81e+00) (-6.44e+01, 1.27e+02) (-2.58e+00, 3.70e+00) (-1.19e+02, 7.36e+01) (-8.54e+01, 1.14e+02) (-1.81e+02, 1.09e+02) (-7.46e+01, 1.23e+02) (2.46e+02, 4.65e+03) (2.82e+03, 1.15e+04)
Version June 1, 2020 submitted to J. Imaging 14 of 15
References273
1. Wardlaw, J.M.; Doubal, F.; Armitage, P.; Chappell, F.; Carpenter, T.; Muñoz Maniega, S.; Farrall, A.; Sudlow,274
C.; Dennis, M.; Dhillon, B. Lacunar stroke is associated with diffuse blood–brain barrier dysfunction.275
Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society276
2009, 65, 194–202.277
2. Kidwell, C.; Burgess, R.; Menon, R.; Warach, S.; Latour, L. Hyperacute injury marker (HARM) in primary278
hemorrhage: a distinct form of CNS barrier disruption. Neurology 2011, 77, 1725–1728.279
3. Thrippleton, M.J.; Backes, W.H.; Sourbron, S.; Ingrisch, M.; van Osch, M.J.; Dichgans, M.; Fazekas, F.;280
Ropele, S.; Frayne, R.; van Oostenbrugge, R.J.; Smith, E.E.; Wardlaw, J.M. Quantifying blood-brain barrier281
leakage in small vessel disease: Review and consensus recommendations. Alzheimer’s & Dementia 2019,282
15, 840–858.283
4. Topakian, R.; Barrick, T.; Howe, F.; Markus, H. Blood–brain barrier permeability is increased in284
normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. Journal of Neurology,285
Neurosurgery & Psychiatry 2010, 81, 192–197.286
5. Muñoz Maniega, S.; Chappell, F.M.; Valdés Hernández, M.C.; Armitage, P.A.; Makin, S.D.; Heye, A.K.;287
Thrippleton, M.J.; Sakka, E.; Shuler, K.; Dennis, M.S.; others. Integrity of normal-appearing white matter:288
influence of age, visible lesion burden and hypertension in patients with small-vessel disease. Journal of289
Cerebral Blood Flow & Metabolism 2017, 37, 644–656.290
6. Wardlaw, J.M.; Makin, S.J.; Valdés-Hernández, M.C.; Armitage, P.A.; Heye, A.K.; Chappell, F.M.;291
Munoz-Maniega, S.; Sakka, E.; Shuler, K.; Dennis, M.S.; others. Blood-brain barrier failure as a core292
mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimer’s &293
Dementia 2017, 13, 634–643.294
7. Bernal, J.; Valdés-Hernández, M.d.C.; Escudero, J.; Armitage, P.A.; Makin, S.; Touyz, R.M.; Wardlaw,295
J.M. Analysis of spatial spectral features of dynamic contrast-enhanced brain magnetic resonance images296
for studying small vessel disease. Annual Conference on Medical Image Understanding and Analysis.297
Springer, 2019, pp. 282–293.298
8. Bernal, J.; Valdés-Hernández, M.d.C.; Escudero, J.; Viksne, L.; Heye, A.K.; Armitage, P.A.; Makin, S.;299
Touyz, R.M.; Wardlaw, J.M. Analysis of dynamic texture and spatial spectral descriptors of dynamic300
contrast-enhanced brain magnetic resonance images for studying small vessel disease. Magnetic resonance301
imaging 2020, 66, 240–247.302
9. Armitage, P.A.; others. Use of dynamic contrast-enhanced MRI to measure subtle blood–brain barrier303
abnormalities. Magnetic resonance imaging 2011, 29, 305–314.304
10. Barnes, S.R.; others. Optimal acquisition and modeling parameters for accurate assessment of low Ktrans305
blood–brain barrier permeability using dynamic contrast-enhanced MRI. Magnetic resonance in medicine306
2016, 75, 1967–1977.307
11. Heye, A.K.; Thrippleton, M.J.; Armitage, P.A.; Valdés-Hernández, M.d.C.; Makin, S.D.; Glatz, A.; Sakka,308
E.; Wardlaw, J.M. Tracer kinetic modelling for DCE-MRI quantification of subtle blood–brain barrier309
permeability. Neuroimage 2016, 125, 446–455.310
12. Valdés-Hernández, M.d.C.; Armitage, P.A.; Thrippleton, M.J.; Chappell, F.; Sandeman, E.; Muñoz Maniega,311
S.; Shuler, K.; Wardlaw, J.M. Rationale, design and methodology of the image analysis protocol for studies312
of patients with cerebral small vessel disease and mild stroke. Brain and behavior 2015, 5, e00415.313
13. Wardlaw, J.M.; Chappell, F.M.; Valdés-Hernández, M.d.C.; Makin, S.D.; Staals, J.; Shuler, K.; Thrippleton,314
M.J.; Armitage, P.A.; Muñoz-Maniega, S.; Heye, A.K.; others. White matter hyperintensity reduction and315
outcomes after minor stroke. Neurology 2017, 89, 1003–1010.316
14. Fazekas, F.; Niederkorn, K.; Schmidt, R.; Offenbacher, H.; Horner, S.; Bertha, G.; Lechner, H. White matter317
signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow318
measurements, and cerebrovascular risk factors. Stroke 1988, 19, 1285–1288.319
15. Staals, J.; Makin, S.D.; Doubal, F.N.; Dennis, M.S.; Wardlaw, J.M. Stroke subtype, vascular risk factors, and320
total MRI brain small-vessel disease burden. Neurology 2014, 83, 1228–1234.321
16. Valdés-Hernández, M.d.C.; Ferguson, K.J.; Chappell, F.M.; Wardlaw, J.M. New multispectral MRI data322
fusion technique for white matter lesion segmentation: method and comparison with thresholding in323
FLAIR images. European radiology 2010, 20, 1684–1691.324
Version June 1, 2020 submitted to J. Imaging 15 of 15
17. Chapter 3 Power spectrum and its applications. In Analysis of Geophysical Potential Fields; Naidu, P.S.;325
Mathew, M., Eds.; Elsevier, 1998; Vol. 5, Advances in Exploration Geophysics, pp. 75 – 143.326
18. Happ, C.; Greven, S. Multivariate functional principal component analysis for data observed on different327
(dimensional) domains. Journal of the American Statistical Association 2018, pp. 1–11.328
19. Bronge, L.; Wahlund, L.O. White matter lesions in dementia: an MRI study on blood-brain barrier329
dysfunction. Dementia and geriatric cognitive disorders 2000, 11, 263–267.330
20. Hanyu, H.; Asano, T.; Tanaka, Y.; Iwamoto, T.; Takasaki, M.; Abe, K. Increased blood-brain barrier331
permeability in white matter lesions of Binswanger’s disease evaluated by contrast-enhanced MRI.332
Dementia and geriatric cognitive disorders 2002, 14, 1–6.333
21. Wardlaw, J.M.; Farrall, A.; Armitage, P.A.; Carpenter, T.; Chappell, F.; Doubal, F.; Chowdhury, D.; Cvoro, V.;334
Dennis, M.S. Changes in background blood–brain barrier integrity between lacunar and cortical ischemic335
stroke subtypes. Stroke 2008, 39, 1327–1332.336
22. Wardlaw, J.M.; Doubal, F.N.; Valdes-Hernandez, M.; Wang, X.; Chappell, F.M.; Shuler, K.; Armitage,337
P.A.; Carpenter, T.C.; Dennis, M.S. Blood–brain barrier permeability and long-term clinical and imaging338
outcomes in cerebral small vessel disease. Stroke 2013, 44, 525–527.339
23. Starr, J.M.; Farrall, A.J.; Armitage, P.; McGurn, B.; Wardlaw, J. Blood–brain barrier permeability in340
Alzheimer’s disease: a case–control MRI study. Psychiatry Research: Neuroimaging 2009, 171, 232–241.341
24. Heye, A.K.; Culling, R.D.; Valdés-Hernández, M.d.C.; Thrippleton, M.J.; Wardlaw, J.M. Assessment of342
blood–brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. NeuroImage:343
Clinical 2014, 6, 262–274.344
25. Brown, W.R.; Thore, C.R. Cerebral microvascular pathology in ageing and neurodegeneration.345
Neuropathology and applied neurobiology 2011, 37, 56–74.346
26. Heye, A.K. Measurement of subtle blood-brain barrier disruption in cerebral small vessel disease using347
dynamic contrast-enhanced magnetic resonance imaging. PhD thesis, The University of Edinburgh, 2015.348
27. Wardlaw, J.M.; Valdés-Hernández, M.C.; Muñoz-Maniega, S. What are white matter hyperintensities made349
of? Relevance to vascular cognitive impairment. Journal of the American Heart Association 2015, 4, e001140.350
28. Shi, Y.; Thrippleton, M.J.; Makin, S.D.; Marshall, I.; Geerlings, M.I.; de Craen, A.J.; van Buchem, M.A.;351
Wardlaw, J.M. Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. Journal352
of Cerebral Blood Flow & Metabolism 2016, 36, 1653–1667.353
29. Bahrani, A.A.; Powell, D.K.; Yu, G.; Johnson, E.S.; Jicha, G.A.; Smith, C.D. White matter hyperintensity354
associations with cerebral blood flow in elderly subjects stratified by cerebrovascular risk. Journal of Stroke355
and Cerebrovascular Diseases 2017, 26, 779–786.356
30. Blair, G.W.; Thrippleton, M.J.; Shi, Y.; Hamilton, I.; Stringer, M.; Chappell, F.M.; Dickie, D.A.; Andrews, P.J.;357
Marshall, I.; Doubal, F.N.; others. Intracranial functional haemodynamic relationships in patients with358
cerebral small vessel disease. bioRxiv 2019, p. 572818.359
31. Biessels, G.J. Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms. The360
Netherlands journal of medicine 1999, 54, 35–45.361
32. Prasad, S.; Sajja, R.K.; Naik, P.; Cucullo, L. Diabetes mellitus and blood-brain barrier dysfunction: an362
overview. Journal of pharmacovigilance 2014, 2, 125.363
33. Xu, R.S. Pathogenesis of diabetic cerebral vascular disease complication. World journal of diabetes 2015,364
6, 54.365
c© 2020 by the authors. Submitted to J. Imaging for possible open access publication366
under the terms and conditions of the Creative Commons Attribution (CC BY) license367
(http://creativecommons.org/licenses/by/4.0/).368
